Exousia Pro Issues Update on Name Change
Marijuana Inc. (OTC PINK:MAJI), operating as Exousia Pro, Inc., has received feedback from FINRA regarding its pending name change application. The clinical-stage biotech company, which focuses on exosome-based treatments for cancer and other diseases, has submitted required documentation including Board minutes and Articles of Amendment to the State of Florida. To facilitate the parent company's name change, the subsidiary's name was changed from Exousia Pro, Inc. to Exousia AI, Inc. According to company president Matthew Dwyer, FINRA's response within the first 30 days of filing indicates positive progress in the process.
Marijuana Inc. (OTC PINK:MAJI), operante come Exousia Pro, Inc., ha ricevuto un riscontro da FINRA riguardo alla sua domanda di cambio nome in sospeso. La compagnia biotech in fase clinica, che si concentra su trattamenti basati su esosomi per il cancro e altre malattie, ha presentato la documentazione necessaria, inclusi i verbali del Consiglio e gli Articoli di Modifica allo Stato della Florida. Per facilitare il cambio di nome della società madre, il nome della filiale è stato cambiato da Exousia Pro, Inc. a Exousia AI, Inc. Secondo il presidente della compagnia, Matthew Dwyer, la risposta di FINRA entro i primi 30 giorni dalla presentazione indica un progresso positivo nel processo.
Marijuana Inc. (OTC PINK:MAJI), que opera como Exousia Pro, Inc., ha recibido comentarios de FINRA sobre su solicitud de cambio de nombre pendiente. La compañía biotecnológica en etapa clínica, que se centra en tratamientos basados en exosomas para el cáncer y otras enfermedades, ha presentado la documentación requerida, incluidos los actas de la Junta y los Artículos de Enmienda al Estado de Florida. Para facilitar el cambio de nombre de la empresa matriz, el nombre de la subsidiaria se cambió de Exousia Pro, Inc. a Exousia AI, Inc. Según el presidente de la compañía, Matthew Dwyer, la respuesta de FINRA dentro de los primeros 30 días de presentación indica un progreso positivo en el proceso.
Marijuana Inc. (OTC PINK:MAJI), Exousia Pro, Inc.로 운영되는 이 회사는 이름 변경 신청에 대한 FINRA의 피드백을 받았습니다. 암 및 기타 질병에 대한 엑소좀 기반 치료에 중점을 둔 임상 단계의 생명공학 회사는 플로리다 주에 이사회 회의록 및 수정 조항을 포함한 필요한 문서를 제출했습니다. 모회사의 이름 변경을 용이하게 하기 위해, 자회사의 이름은 Exousia Pro, Inc.에서 Exousia AI, Inc.로 변경되었습니다. 회사의 회장인 매튜 드와이어에 따르면, 제출 후 첫 30일 이내의 FINRA의 응답은 프로세스에서 긍정적인 진전을 나타냅니다.
Marijuana Inc. (OTC PINK:MAJI), opérant sous le nom de Exousia Pro, Inc., a reçu des retours de la FINRA concernant sa demande de changement de nom en cours. La société biotechnologique en phase clinique, qui se concentre sur des traitements basés sur des exosomes pour le cancer et d'autres maladies, a soumis la documentation requise, y compris les procès-verbaux du conseil et les articles de modification à l'État de Floride. Pour faciliter le changement de nom de la société mère, le nom de la filiale a été changé de Exousia Pro, Inc. à Exousia AI, Inc. Selon le président de la société, Matthew Dwyer, la réponse de la FINRA dans les 30 premiers jours suivant le dépôt indique des progrès positifs dans le processus.
Marijuana Inc. (OTC PINK:MAJI), das als Exousia Pro, Inc. tätig ist, hat von FINRA Rückmeldungen zu seinem ausstehenden Antrag auf Namensänderung erhalten. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf exosom-basierte Behandlungen für Krebs und andere Krankheiten konzentriert, hat die erforderlichen Unterlagen, einschließlich Protokollen des Vorstands und Änderungsartikeln, beim Staat Florida eingereicht. Um die Namensänderung des Mutterunternehmens zu erleichtern, wurde der Name der Tochtergesellschaft von Exousia Pro, Inc. in Exousia AI, Inc. geändert. Laut dem Präsidenten des Unternehmens, Matthew Dwyer, zeigt die Antwort von FINRA innerhalb der ersten 30 Tage nach Einreichung einen positiven Fortschritt im Prozess.
- FINRA's prompt response (within 30 days) indicates administrative progress
- None.
ORLANDO, FLORIDA / ACCESS Newswire / April 3, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to announce that the Company has received comments from FINRA regarding the name change.
FINRA has requested specific Board minutes and the stamped Articles of Amendment from the State of Florida showing the name change from Marijuana, Inc. to Exousia Pro, Inc.
We submitted the Articles of Amendment to the filer yesterday, and they will be forwarded to the State this morning. To facilitate the Name change, the name of our subsidiary had to be changed from Exousia Pro, Inc. to Exousia AI, Inc., to release the name for the parent company.
"This is a positive indicator that the process is moving along, as evidenced by hearing from FINRA within the first 30 days of the filing," said Matthew Dwyer, President of Exousia Pro, Inc.
About us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
What is the status of MAJI's name change from Marijuana Inc. to Exousia Pro?
Why did MAJI's subsidiary change its name to Exousia AI?
What is MAJI's current business focus as Exousia Pro?
How long did it take for FINRA to respond to MAJI's name change application?
